Gilead, LEO Pharma Partner to Accelerate Oral STAT6 Development Program
Gilead Sciences, Inc. and LEO Pharma are partnering to accelerate the development and commercialization of LEO Pharma’s small molecule oral signal transducer and activator of transcription 6 (STAT6) programs for the potential treatment of patients with inflammatory diseases. STAT6 is the specific transcription factor required for interleukin (IL)-4 and IL-13 cytokine signaling, which are clinically […]